dc.contributor.author | Muller, I | |
dc.contributor.author | Kilburn, LS | |
dc.contributor.author | Taylor, PN | |
dc.contributor.author | Barrett-Lee, PJ | |
dc.contributor.author | Bliss, JM | |
dc.contributor.author | Ellis, P | |
dc.contributor.author | Ludgate, ME | |
dc.contributor.author | Dayan, CM | |
dc.date.accessioned | 2017-10-05T15:15:09Z | |
dc.date.accessioned | 2020-06-22T10:04:21Z | |
dc.date.issued | 2017-07-01 | |
dc.identifier.citation | European thyroid journal, 2017, 6 (4), pp. 197 - 207 | |
dc.identifier.issn | 2235-0640 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3760 | |
dc.identifier.eissn | 2235-0802 | |
dc.identifier.doi | 10.1159/000460246 | |
dc.description.abstract | BACKGROUND: Small-scale studies correlated the presence of thyroid autoimmunity with both improved or worsened breast cancer outcome. OBJECTIVES: We aimed to clarify this association in a large cohort using the phase III, randomized, controlled Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). METHODS: TACT women >18 years old with node-positive or high-risk node-negative early breast cancer (pT1-3a, pN0-1, M0), with stored plasma (n = 1,974), taken 15.5 (median; IQR 7.0-24.0) months after breast surgery were studied. Patients had also received chemotherapy (100%), radiotherapy (1,745/1,974; 88.4%), hormonal therapy (1,378/ 1,974; 69.8%), or trastuzumab (48/1,974; 2.4%). History of thyroid diseases and/or related treatments was not available. The prognostic significance of autoantibodies to thyroid peroxidase (TPOAb; positive ≥6 kIU/L), free-thyroxine and thyrotropin (combined: euthyroid, hypothyroid, hyperthyroid) was evaluated for disease-free survival (DFS), overall-survival (OS), and time-to-recurrence (TTR), with Cox regression models in univariate and multivariable analyses. The extended median follow-up was 97.5 months. RESULTS: No difference in DFS was found by TPOAb status (unadjusted hazard ratio [HR]: 0.97, 95%CI: 0.78-1.19; p = 0.75) and/or thyroid function (unadjusted HR [hypothyroid vs. euthyroid]: 1.15, 95% CI: 0.79-1.68; p = 0.46; unadjusted HR [hyperthyroid vs. euthyroid]: 1.14, 95% CI: 0.82-1.61; p = 0.44). Similar results were obtained for OS, TTR, multivariable analyses, when TPOAb titre by tertiles was considered, and in a subgroup of 123 patients with plasma collected before adjuvant treatments. CONCLUSIONS: No evidence for a prognostic role of TPOAb and/or thyroid function in moderate-to-high-risk early breast cancer was found in the largest and longest observational study to date. | |
dc.format | Print-Electronic | |
dc.format.extent | 197 - 207 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | KARGER | |
dc.relation.replaces | https://repository.icr.ac.uk/handle/internal/848 | |
dc.relation.replaces | internal/848 | |
dc.relation.replaces | internal/820 | |
dc.relation.replaces | https://repository.icr.ac.uk/handle/internal/820 | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.title | TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-02-07 | |
rioxxterms.funder | The Institute of Cancer Research | |
rioxxterms.identifier.project | Unspecified | |
rioxxterms.versionofrecord | 10.1159/000460246 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | European thyroid journal | |
pubs.issue | 4 | |
pubs.notes | Indefinite | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Published | |
pubs.volume | 6 | |
pubs.embargo.terms | Indefinite | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Kilburn, Lucy | |
dc.contributor.icrauthor | Bliss, Judith | |